Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study

e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study

The tumor microenvironment consists of the stromal background with a variety of cells such as fibroblasts, endothelial cells, and lymphocytes. The tumor-stroma ratio (TSR) is the amount of tumor relative to the amount of stroma in the primary tumor [2-4]. Patients with a high amount of stroma (stroma-high) have a worse prognosis compared to those harboring tumors with a low amount of stroma (stroma-low) in multiple types of cancer [5-13].

Marloes A Smit, Gabi W van Pelt, Elisabeth MC Dequeker, Raed Al Dieri, Rob AEM Tollenaar, J Han JM van Krieken, Wilma E Mesker, UNITED Group

JMIR Form Res 2021;5(3):e19408

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study

Part 2 will involve validation in a prospective cohort of colon cancer stage II-III patients within this multicenter setting. The inclusion is expected to take 3 years, with a 3-year follow-up period. In the UNITED study, all patients are diagnosed with pathological stage (p-stage) II or p-stage III colon cancer. For e-learning, H&E-stained slides of stage II-III colon cancer patients were selected in a retrospective manner.

Marloes Smit, Gabi van Pelt, Annet Roodvoets, Elma Meershoek-Klein Kranenbarg, Hein Putter, Rob Tollenaar, J Han van Krieken, Wilma Mesker

JMIR Res Protoc 2019;8(6):e13464